

# J Henricus Van Krieken

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6273947/publications.pdf>

Version: 2024-02-01

165  
papers

9,939  
citations

71061

41  
h-index

36008

97  
g-index

167  
all docs

167  
docs citations

167  
times ranked

15589  
citing authors

#	ARTICLE	IF	CITATIONS
1	ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. <i>Annals of Oncology</i> , 2016, 27, 1386-1422.	0.6	2,545
2	A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. <i>Modern Pathology</i> , 2018, 31, 1770-1786.	2.9	739
3	MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013, 121, 4021-4031.	0.6	596
4	Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline <i>CDH1</i> mutation carriers. <i>Journal of Medical Genetics</i> , 2015, 52, 361-374.	1.5	479
5	A germline homozygous mutation in the base-excision repair gene <i>NTHL1</i> causes adenomatous polyposis and colorectal cancer. <i>Nature Genetics</i> , 2015, 47, 668-671.	9.4	311
6	Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. <i>Leukemia</i> , 2012, 26, 2103-2113.	3.3	301
7	Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. <i>Journal of Clinical Investigation</i> , 2011, 121, 3100-3108.	3.9	271
8	KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. <i>British Journal of Cancer</i> , 2011, 104, 1020-1026.	2.9	262
9	Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. <i>Lancet Oncology</i> , The, 2011, 12, 49-55.	5.1	232
10	CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , 2013, 121, 2715-2724.	0.6	206
11	Cellular angiofibroma: analysis of 25 cases emphasizing its relationship to spindle cell lipoma and mammary-type myofibroblastoma. <i>Modern Pathology</i> , 2011, 24, 82-89.	2.9	159
12	Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. <i>Haematologica</i> , 2013, 98, 255-263.	1.7	142
13	Cancer risk in patients with Noonan syndrome carrying a PTPN11 mutation. <i>European Journal of Human Genetics</i> , 2011, 19, 870-874.	1.4	141
14	Recurrence and variability of germline <i>EPCAM</i> deletions in Lynch syndrome. <i>Human Mutation</i> , 2011, 32, 407-414.	1.1	137
15	Prevalence and Clinical Implications of Epstein-Barr Virus Infection in <i>De Novo</i> Diffuse Large B-Cell Lymphoma in Western Countries. <i>Clinical Cancer Research</i> , 2014, 20, 2338-2349.	3.2	117
16	Scoring the tumor-stroma ratio in colon cancer: procedure and recommendations. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 473, 405-412.	1.4	113
17	Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. <i>Modern Pathology</i> , 2014, 27, 958-971.	2.9	112
18	<i>CDH1</i> -related hereditary diffuse gastric cancer syndrome: Clinical variations and implications for counseling. <i>International Journal of Cancer</i> , 2012, 131, 367-376.	2.3	110

#	ARTICLE	IF	CITATIONS
19	Role of Dectin-2 for Host Defense against Systemic Infection with <i>Candida glabrata</i> . <i>Infection and Immunity</i> , 2014, 82, 1064-1073.	1.0	100
20	The tumourâ€‘stroma ratio in colon cancer: the biological role and its prognostic impact. <i>Histopathology</i> , 2018, 73, 197-206.	1.6	97
21	Prognostic impact of concurrent <i>MYC</i> and <i>BCL6</i> rearrangements and expression in <i>de novo</i> diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2016, 7, 2401-2416.	0.8	93
22	Recognizing nodal marginal zone lymphoma: recent advances and pitfalls. A systematic review. <i>Haematologica</i> , 2013, 98, 1003-1013.	1.7	85
23	External Quality Assessment for <i>KRAS</i> Testing Is Needed: Setup of a European Program and Report of the First Jointed Regional Quality Assessment Rounds. <i>Oncologist</i> , 2011, 16, 467-478.	1.9	83
24	Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBL. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 5-20.	1.4	82
25	Clinical and biological significance of <i>de novo</i> CD5+ diffuse large B-cell lymphoma in Western countries. <i>Oncotarget</i> , 2015, 6, 5615-5633.	0.8	72
26	Familial gastric cancer: guidelines for diagnosis, treatment and periodic surveillance. <i>Familial Cancer</i> , 2012, 11, 363-369.	0.9	71
27	Guideline on the requirements of external quality assessment programs in molecular pathology. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013, 462, 27-37.	1.4	70
28	Epsteinâ€‘Barr Virus in Inflammatory Bowel Disease: The Spectrum of Intestinal Lymphoproliferative Disorders. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 398-403.	0.6	70
29	Identification of candidate predisposing copy number variants in familial and earlyâ€‘onset colorectal cancer patients. <i>International Journal of Cancer</i> , 2011, 129, 1635-1642.	2.3	66
30	Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma. <i>Neoplasia</i> , 2018, 20, 574-593.	2.3	64
31	Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2015, 6, 5597-5614.	0.8	61
32	Clinical Implications of Phosphorylated STAT3 Expression in <i>De Novo</i> Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2014, 20, 5113-5123.	3.2	60
33	Overlap, Common Features, and Essential Differences in Pediatric Granulomatous Inflammatory Bowel Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2010, 51, 690-697.	0.9	56
34	Clinical features, tumor biology, and prognosis associated with <i>MYC</i> rearrangement and <i>Myc</i> overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. <i>Modern Pathology</i> , 2015, 28, 1555-1573.	2.9	48
35	Clinical and Biologic Significance of <i>MYC</i> Genetic Mutations in <i>De Novo</i> Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2016, 22, 3593-3605.	3.2	48
36	Histopathological, Molecular, and Genetic Profile of Hereditary Diffuse Gastric Cancer: Current Knowledge and Challenges for the Future. <i>Advances in Experimental Medicine and Biology</i> , 2016, 908, 371-391.	0.8	47

#	ARTICLE	IF	CITATIONS
37	Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma. <i>Leukemia</i> , 2017, 31, 625-636.	3.3	47
38	Tetraspanin CD37 protects against the development of B cell lymphoma. <i>Journal of Clinical Investigation</i> , 2016, 126, 653-666.	3.9	47
39	Inter-observer variation in the histological diagnosis of polyps in colorectal cancer screening. <i>Histopathology</i> , 2011, 58, 974-981.	1.6	46
40	The Role of Dectin-2 for Host Defense Against Disseminated Candidiasis. <i>Journal of Interferon and Cytokine Research</i> , 2016, 36, 267-276.	0.5	45
41	Novel developments in the pathogenesis and diagnosis of extranodal marginal zone lymphoma. <i>Journal of Hematopathology</i> , 2017, 10, 91-107.	0.2	45
42	Preparing pathology for personalized medicine: possibilities for improvement of the pre-analytical phase. <i>Histopathology</i> , 2011, 59, 1-7.	1.6	44
43	Sequential immunohistochemistry: a promising new tool for the pathology laboratory. <i>Histopathology</i> , 2014, 65, 651-657.	1.6	44
44	Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013, 121, 4529-4540.	0.6	41
45	Large variation between hospitals and pathology laboratories in lymph node evaluation in colon cancer and its impact on survival, a nationwide population-based study in The Netherlands. <i>Annals of Oncology</i> , 2011, 22, 110-117.	0.6	39
46	European Consensus Conference for external quality assessment in molecular pathology. <i>Annals of Oncology</i> , 2013, 24, 1958-1963.	0.6	39
47	External Quality Assessment Unravels Interlaboratory Differences in Quality of RAS Testing for Anti-EGFR Therapy in Colorectal Cancer. <i>Oncologist</i> , 2015, 20, 257-262.	1.9	39
48	AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma. <i>American Journal of Pathology</i> , 2017, 187, 1700-1716.	1.9	39
49	Detection of EGFR Variants in Plasma. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 483-494.	1.2	37
50	Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy. <i>Leukemia</i> , 2018, 32, 353-363.	3.3	36
51	Prognostic impact of c-Rel nuclear expression and c-REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2015, 6, 23157-23180.	0.8	35
52	Unraveling genetic predisposition to familial or early onset gastric cancer using germline whole-exome sequencing. <i>European Journal of Human Genetics</i> , 2017, 25, 1246-1252.	1.4	34
53	T-cell Landscape in a Primary Melanoma Predicts the Survival of Patients with Metastatic Disease after Their Treatment with Dendritic Cell Vaccines. <i>Cancer Research</i> , 2016, 76, 3496-3506.	0.4	33
54	c-RAS mutation prevalence among patients with metastatic colorectal cancer: a meta-analysis of real-world data. <i>Biomarkers in Medicine</i> , 2017, 11, 751-760.	0.6	33

#	ARTICLE	IF	CITATIONS
55	Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma-is it necessary?. <i>Oncotarget</i> , 2015, 6, 13933-13945.	0.8	33
56	Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: A report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Cancer</i> , 2014, 120, 1818-1829.	2.0	32
57	RelA NF- $\kappa$ B subunit activation as a therapeutic target in diffuse large B-cell lymphoma. <i>Aging</i> , 2016, 8, 3321-3340.	1.4	29
58	RAS testing in metastatic colorectal cancer: advances in Europe. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 383-396.	1.4	27
59	KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assurance. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013, 462, 39-46.	1.4	26
60	HNF4A immunohistochemistry facilitates distinction between primary and metastatic breast and gastric carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 464, 673-679.	1.4	26
61	The evaluation of colon biopsies using virtual microscopy is reliable. <i>Histopathology</i> , 2013, 63, 114-121.	1.6	23
62	Three Rounds of External Quality Assessment in France to Evaluate the Performance of 28 Platforms for Multiparametric Molecular Testing in Metastatic Colorectal and Non-Small Cell Lung Cancer. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 205-214.	1.2	23
63	Higher Quality of Molecular Testing, an Unfulfilled Priority. <i>Journal of Molecular Diagnostics</i> , 2014, 16, 371-377.	1.2	22
64	Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2022, 28, 972-983.	3.2	22
65	Variation in Lymph Node Evaluation in Rectal Cancer: A Dutch Nationwide Population-Based Study. <i>Annals of Surgical Oncology</i> , 2011, 18, 386-395.	0.7	21
66	Application of Microfluidic Technology to the BIOMED-2 Protocol for Detection of B-Cell Clonality. <i>Journal of Molecular Diagnostics</i> , 2012, 14, 30-37.	1.2	21
67	Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. <i>Modern Pathology</i> , 2015, 28, 1297-1314.	2.9	21
68	Recurrent mutations in genes involved in nuclear factor- $\kappa$ B signalling in nodal marginal zone lymphoma—diagnostic and therapeutic implications. <i>Histopathology</i> , 2017, 70, 174-184.	1.6	21
69	Accreditation, setting and experience as indicators to assure quality in oncology biomarker testing laboratories. <i>British Journal of Cancer</i> , 2018, 119, 605-614.	2.9	21
70	T(14;18)(q32;q21) involving MALT1 and IGH genes occurs in extranodal diffuse large B-cell lymphomas of the breast and testis. <i>Modern Pathology</i> , 2013, 26, 421-427.	2.9	20
71	Immunohistochemical differentiation between follicular lymphoma and nodal marginal zone lymphoma - combined performance of multiple markers. <i>Haematologica</i> , 2015, 100, e358-e360.	1.7	20
72	Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents. <i>Molecular Cancer Research</i> , 2021, 19, 249-260.	1.5	20

#	ARTICLE	IF	CITATIONS
73	Uniform Noting for International Application of the Tumor-Stroma Ratio as an Easy Diagnostic Tool: Protocol for a Multicenter Prospective Cohort Study. <i>JMIR Research Protocols</i> , 2019, 8, e13464.	0.5	20
74	Reduced Circumferential Resection Margin Involvement in Rectal Cancer Surgery: Results of the Dutch Surgical Colorectal Audit. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1111-1119.	2.3	19
75	p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function. <i>Aging</i> , 2016, 8, 345-365.	1.4	19
76	Mutation analysis of KRAS prior to targeted therapy in colorectal cancer: development and evaluation of quality by a European external quality assessment scheme. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2011, 459, 155-160.	1.4	18
77	Molecular pathogenesis and histologic and clinical features of extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue type. <i>Leukemia and Lymphoma</i> , 2012, 53, 1032-1045.	0.6	18
78	Neoadjuvant Sorafenib Treatment of Clear Cell Renal Cell Carcinoma and Release of Circulating Tumor Fragments. <i>Neoplasia</i> , 2014, 16, 221-228.	2.3	18
79	A 20-year population-based study on the epidemiology, clinical features, treatment, and outcome of nodular lymphocyte predominant Hodgkin lymphoma. <i>Annals of Hematology</i> , 2016, 95, 417-423.	0.8	18
80	High frequency of inactivating tetraspanin CD37 mutations in diffuse large B-cell lymphoma at immune-privileged sites. <i>Blood</i> , 2019, 134, 946-950.	0.6	18
81	Trends in incidence, therapy and outcome of localized nodal and extranodal marginal zone lymphomas: declining incidence and inferior outcome for gastrointestinal sites. <i>Leukemia and Lymphoma</i> , 2013, 54, 1891-1897.	0.6	17
82	Evaluation of NF- $\kappa$ B subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions. <i>Modern Pathology</i> , 2015, 28, 1202-1213.	2.9	17
83	Psychological distress in newly diagnosed colorectal cancer patients following microsatellite instability testing for Lynch syndrome on the pathologist's initiative. <i>Familial Cancer</i> , 2012, 11, 259-267.	0.9	16
84	External Quality Assessment Identifies Training Needs to Determine the Neoplastic Cell Content for Biomarker Testing. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 455-464.	1.2	16
85	Neoplastic cell percentage estimation in tissue samples for molecular oncology: recommendations from a modified Delphi study. <i>Histopathology</i> , 2019, 75, 312-319.	1.6	15
86	Clinical and pathological features of testicular diffuse large B-cell lymphoma: a heterogeneous disease. <i>Leukemia and Lymphoma</i> , 2012, 53, 242-246.	0.6	14
87	Gastric cancer in three relatives of a patient with a biallelic IL12RB1 mutation. <i>Familial Cancer</i> , 2015, 14, 89-94.	0.9	14
88	Lymphocytic variant hypereosinophilic syndrome progressing to angioimmunoblastic T-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 1891-1894.	0.6	14
89	Multispectral imaging for highly accurate analysis of tumour-infiltrating lymphocytes in primary melanoma. <i>Histopathology</i> , 2017, 70, 643-649.	1.6	14
90	High mRNA expression of splice variant SYK short correlates with hepatic disease progression in chemonaive lymph node negative colon cancer patients. <i>PLoS ONE</i> , 2017, 12, e0185607.	1.1	14

#	ARTICLE	IF	CITATIONS
91	Implementation of Formalin-Fixed, Paraffin-Embedded Cell Line Pellets as High-Quality Process Controls in Quality Assessment Programs for KRAS Mutation Analysis. <i>Journal of Molecular Diagnostics</i> , 2012, 14, 187-191.	1.2	13
92	Clinical features of patients with nodal marginal zone lymphoma compared to follicular lymphoma: similar presentation, but differences in prognostic factors and rate of transformation. <i>Leukemia and Lymphoma</i> , 2016, 57, 1649-1656.	0.6	13
93	Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations. <i>British Journal of Cancer</i> , 2017, 117, 1685-1688.	2.9	13
94	Direct inhibition of STAT signaling by platinum drugs contributes to their anti-cancer activity. <i>Oncotarget</i> , 2017, 8, 54434-54443.	0.8	13
95	A practical approach to diagnostic Ig/TCR clonality evaluation in clinical pathology. <i>Journal of Hematopathology</i> , 2012, 5, 17-25.	0.2	12
96	RAS testing in metastatic colorectal cancer: excellent reproducibility amongst 17 Dutch pathology centers. <i>Oncotarget</i> , 2015, 6, 15681-15689.	0.8	12
97	Evaluation of a panel of expert pathologists: review of the diagnosis and histological classification of Hodgkin and non-Hodgkin lymphomas in a population-based cancer registry. <i>Leukemia and Lymphoma</i> , 2014, 55, 1018-1022.	0.6	11
98	The homogeneous mutation status of a 22 gene panel justifies the use of serial sections of colorectal cancer tissue for external quality assessment. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 467, 273-278.	1.4	11
99	Centralised multidisciplinary re-evaluation of diagnostic procedures in patients with newly diagnosed Hodgkin lymphoma. <i>Annals of Oncology</i> , 2012, 23, 2676-2681.	0.6	10
100	Panitumumab Use in Metastatic Colorectal Cancer and Patterns of KRAS Testing: Results from a Europe-Wide Physician Survey and Medical Records Review. <i>PLoS ONE</i> , 2015, 10, e0140717.	1.1	9
101	e-Learning for Instruction and to Improve Reproducibility of Scoring Tumor-Stroma Ratio in Colon Carcinoma: Performance and Reproducibility Assessment in the UNITED Study. <i>JMIR Formative Research</i> , 2021, 5, e19408.	0.7	9
102	New developments in the pathology of malignant lymphoma: a review of the literature published from May to August 2017. <i>Journal of Hematopathology</i> , 2017, 10, 65-73.	0.2	8
103	Tumour-stroma ratio outperforms tumour budding as biomarker in colon cancer: a cohort study. <i>International Journal of Colorectal Disease</i> , 2021, 36, 2729-2737.	1.0	8
104	Undertreatment of patients with localized extranodal compared with nodal diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 1698-1705.	0.6	7
105	A subset of low-grade B cell lymphomas with a follicular growth pattern but without a BCL2 translocation shows features suggestive of nodal marginal zone lymphoma. <i>Journal of Hematopathology</i> , 2016, 9, 3-8.	0.2	7
106	Pathways towards indolent B-cell lymphoma – Etiology and therapeutic strategies. <i>Blood Reviews</i> , 2017, 31, 426-435.	2.8	7
107	RAS testing for colorectal cancer patients is reliable in European laboratories that pass external quality assessment. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 717-725.	1.4	7
108	Variation in guideline adherence in non-Hodgkin's lymphoma care: impact of patient and hospital characteristics. <i>BMC Cancer</i> , 2015, 15, 578.	1.1	6

#	ARTICLE	IF	CITATIONS
109	Quality to rely on: meeting report of the 5th Meeting of External Quality Assessment, Naples 2016. ESMO Open, 2016, 1, e000114.	2.0	6
110	The ileo neo rectal anastomosis: long-term results of surgical innovation in patients after ulcerative colitis and familial adenomatous polyposis. International Journal of Colorectal Disease, 2013, 28, 111-118.	1.0	5
111	Immunoglobulin rearrangement analysis from multiple lesions in the same patient using next-generation sequencing. Histopathology, 2015, 67, 843-858.	1.6	5
112	Higher cytoplasmic and nuclear poly(ADP-ribose) polymerase expression in familial than in sporadic breast cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 461, 425-431.	1.4	4
113	The times have changed: molecular pathology is here to stay. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 460, 129-130.	1.4	3
114	Precision medicine. Journal of Hematopathology, 2013, 6, 1-1.	0.2	3
115	Limited diagnostic value of microsatellite instability associated pathology features in colorectal cancer. Familial Cancer, 2014, 13, 351-359.	0.9	3
116	Trends in quality of non-Hodgkin's lymphoma care: is it getting better?. Annals of Hematology, 2015, 94, 1195-1203.	0.8	3
117	New developments in the pathology of malignant lymphoma. A review of the literature published from January-April 2016. Journal of Hematopathology, 2016, 9, 73-83.	0.2	3
118	New developments in the pathology of malignant lymphoma. A review of the literature published from September 2015-December 2015. Journal of Hematopathology, 2016, 9, 19-27.	0.2	3
119	New developments in the pathology of malignant lymphoma: a review of the literature published from January to April 2017. Journal of Hematopathology, 2017, 10, 25-33.	0.2	3
120	New developments in the pathology of malignant lymphoma. A review of the literature published from September-August 2017. Journal of Hematopathology, 2017, 10, 117-127.	0.2	3
121	Daily practice in guideline adherence to adjuvant chemotherapy in stage III colon cancer and predictors of outcome. European Journal of Surgical Oncology, 2021, 47, 2060-2068.	0.5	3
122	High prevalence of adverse prognostic genetic aberrations and unmutated IGHV genes in small lymphocytic lymphoma as compared to chronic lymphocytic leukemia. Journal of Hematopathology, 2011, 4, 189-197.	0.2	2
123	Do Pre-Analytical Parameters Explain KRAS Test Sensitivity Disparities?. Journal of Molecular Diagnostics, 2012, 14, 631-633.	1.2	2
124	Identification of IG-clonality status as a pre-treatment predictor for mortality in patients with immunodeficiency-associated Epstein-Barr virus-related lymphoproliferative disorders. Haematologica, 2015, 100, e152-e154.	1.7	2
125	New developments in the pathology of malignant lymphoma: a review of the literature published from May 2015-September 2015. Journal of Hematopathology, 2015, 8, 225-234.	0.2	2
126	New developments in the pathology of malignant lymphoma: a review of literature published from January 2015 to April 2015. Journal of Hematopathology, 2015, 8, 71-79.	0.2	2



#	ARTICLE	IF	CITATIONS
127	New developments in the pathology of malignant lymphoma: a review of the literature published from Juneâ€“August 2016. Journal of Hematopathology, 2016, 9, 129-134.	0.2	2
128	How we do: optimizing bone marrow biopsy logistics for sign-out within 2Âdays. Journal of Hematopathology, 2016, 9, 67-71.	0.2	2
129	Diagnosing and classifying malignant lymphomas is improved by referring cases to a panel of expert pathologists. Journal of Hematopathology, 2013, 6, 179-185.	0.2	1
130	New developments in the pathology of malignant lymphoma: a review of the literature published from October 2014â€“December 2014. Journal of Hematopathology, 2015, 8, 21-29.	0.2	1
131	Are we making progress?. Journal of Hematopathology, 2016, 9, 51-51.	0.2	1
132	Editorial: when to be an author?. Journal of Hematopathology, 2017, 10, 89-90.	0.2	1
133	Memento for interprofessional learning. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 755-756.	1.4	1
134	Use of RNA Electroporated DC for Activation of LRH-1 Specific Cytotoxic T Lymphocytes in the Treatment of Lymphoid Malignancies.. Blood, 2006, 108, 138-138.	0.6	1
135	Are we making progress?. Journal of Hematopathology, 2010, 3, 59-59.	0.2	0
136	New developments in the pathology of malignant lymphoma. A review of the literature published from August 2010â€“October 2010. Journal of Hematopathology, 2010, 3, 167-174.	0.2	0
137	The times they are a-changin'. Journal of Hematopathology, 2011, 4, 1-1.	0.2	0
138	New developments in the pathology of malignant lymphoma: a review of the literature published from November 2010â€“January 2011. Journal of Hematopathology, 2011, 4, 31-43.	0.2	0
139	Crisis? What crisis?. Journal of Hematopathology, 2011, 4, 133-133.	0.2	0
140	New developments in the pathology of malignant lymphoma. A review of the literature published from February 2011 to August 2011. Journal of Hematopathology, 2011, 4, 135-144.	0.2	0
141	Rising costs of health care and pathology: cause or solution?. Journal of Hematopathology, 2011, 4, 185-185.	0.2	0
142	What we talk about when we talk about T-cell lymphomas. Journal of Hematopathology, 2012, 5, 289-289.	0.2	0
143	Welcome to Lisbon!. Journal of Hematopathology, 2012, 5, 105-105.	0.2	0
144	New developments in the pathology of malignant lymphoma. A review of the literature published from January 2012â€“July 2012. Journal of Hematopathology, 2012, 5, 149-157.	0.2	0

#	ARTICLE	IF	CITATIONS
145	Editorial: the second special issue of the Journal of Hematopathology. Journal of Hematopathology, 2012, 5, 1-1.	0.2	0
146	Clonality testing: teamwork by pathologist and molecular biologist. Journal of Hematopathology, 2012, 5, 3-5.	0.2	0
147	To publish or perish. Journal of Hematopathology, 2013, 6, 55-55.	0.2	0
148	Cancer, or not. Journal of Hematopathology, 2013, 6, 119-119.	0.2	0
149	New developments in the pathology of malignant lymphoma. A review of the literature published from Juneâ€“August 2014. Journal of Hematopathology, 2014, 7, 103-108.	0.2	0
150	Lymphomas in Istanbul. Journal of Hematopathology, 2014, 7, 145-145.	0.2	0
151	New and old questions. Journal of Hematopathology, 2014, 7, 93-93.	0.2	0
152	Editorial for the Journal of Hematopathology: crisis in science?. Journal of Hematopathology, 2014, 7, 1-1.	0.2	0
153	New developments in the pathology of malignant lymphoma. A review of the literature published from August 2013 to December 2013. Journal of Hematopathology, 2014, 7, 15-25.	0.2	0
154	Grey zone lymphomas. Journal of Hematopathology, 2014, 7, 47-47.	0.2	0
155	The folly of impact factors: some solutions. Journal of Hematopathology, 2015, 8, 49-49.	0.2	0
156	We are not our genes. Journal of Hematopathology, 2015, 8, 201-202.	0.2	0
157	The folly of impact factors. Journal of Hematopathology, 2015, 8, 1-1.	0.2	0
158	Paediatric hematopathology: something real special. Journal of Hematopathology, 2015, 8, 99-99.	0.2	0
159	Open access and data. Journal of Hematopathology, 2016, 9, 105-105.	0.2	0
160	We need to be (much) better. Journal of Hematopathology, 2016, 9, 1-1.	0.2	0
161	Quality in pathology. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 311-312.	1.4	0
162	Will the liquid biopsy replace traditional hematopathology?. Journal of Hematopathology, 2017, 10, 1-1.	0.2	0

#	ARTICLE	IF	CITATIONS
163	Targeting the environment. Journal of Hematopathology, 2017, 10, 47-47.	0.2	0
164	Awareness of KRAS testing by oncologists and panitumumab use in colorectal cancer patients: A European survey.. Journal of Clinical Oncology, 2015, 33, 547-547.	0.8	0
165	Improving hospital care for patients with non-Hodgkin's lymphomas.. Journal of Clinical Oncology, 2016, 34, 6593-6593.	0.8	0